[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365636-105":59,"doc-detail-365636-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","tumor-suppressing-function-of-slc16a7-in-bladder-cancer-and-its-pan-cancer-analysis","Tumor suppressing function of SLC16A7 in bladder cancer and its pan-cancer analysis","","Bladder cancer (BCa) is a highly recurrent malignancy with substantial mortality. SLC16A7, a solute carrier 16 family member encoding monocarboxylate transporters, participates in proton-coupled metabolite transport and may regulate tumor development and immunity. This study integrates pan-cancer bioinformatics with experimental validation to determine how SLC16A7 relates to prognosis, tumor progression, mutation and instability features, and immune regulation, with BCa as the primary focus.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/tumor-suppressing-function-of-slc16a7-in-bladder-cancer-and-its-pan-cancer-analysis/365636/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/tumor-suppressing-function-of-slc16a7-in-bladder-cancer-and-its-pan-cancer-analysis/365636.png","ImageObject",300,407,{"name":92,"@type":93},"Maya Linwood","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What role does SLC16A7 play in cancer based on this study?","Question",{"text":112,"@type":113},"SLC16A7 shows tumor-suppressive properties, with downregulation in most cancers and links to better prognosis in bladder cancer. It is also associated with immune response signatures and improved survival outcomes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was SLC16A7 analyzed across cancers?",{"text":117,"@type":113},"The study used comprehensive pan-cancer data from 33 tumor datasets, assessing relationships between SLC16A7 expression and clinicopathological features, prognosis indicators, TMB, MSI, immune infiltration, and immune-related gene expression.",{"name":119,"@type":110,"acceptedAnswer":120},"What experimental evidence supports the findings in bladder cancer?",{"text":121,"@type":113},"BCa tissue and cell line measurements showed reduced SLC16A7 expression versus normal counterparts. Functional assays indicated that SLC16A7 inhibits BCa progression and promotes CD8+ T cell chemotaxis and tumor-killing in the tumor microenvironment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365636,1790501992,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Xu etal. BMC Cancer (2025) 25:932 BMC Cancer  \n[https://doi.org/10.1186/s12885-025-14345-z](https://doi.org/10.1186/s12885-025-14345-z)  \nRESEARCH Open Access  \nTumor suppressing function ofSLC16A7  in bladder cancer and its pan-cancer analysis  \nMingjie Xu 1†, Jiatong Zhou 1†, Jiancheng Lv 1* andYu Zhang2*  \nAbstract  \nBackground Bladder cancer (BCa), a prevalent malignancy of the urinary tract, is associated with high recurrence and mortality rates. SLC16A7, a member of the solute carrier family 16 (SLC16), encodes monocarboxylate transporters that are involved in the proton-coupled transport of metabolites, including lactate, pyruvate, and ketone bodies, across cell membranes. Evidence suggests that SLC16A7 exhibits variable expression in cancers and may influence tumor development, progression, and immune regulation. This study examined the role ofSLC16A7 in cancer prognosis, progression, and immune regulation, focusing on BCa.  \nMethods A comprehensive analysis was conducted to evaluate the clinical and immunological relevance ofSLC16A7 across multiple cancer types using data from 33 tumor datasets from ‘The Cancer Genome Atlas (TCGA) . ’ Associations between SLC16A7 expression and clinicopathological features, prognostic indicators, tumor mutation burden (TMB), microsatellite instability (MSI), immune cell infiltration, and immune-related gene expression were systematically analyzed. Experimental validation was performed to assess SLC16A7 expression in the BCa tissues and cell lines. The prognostic value ofSLC16A7 was confirmed using clinical follow-up data from an independent patient cohort. Functional studies included proliferation assays to investigate the effect of SLC16A7. CD8 + T cells were obtained from the peripheral blood of healthy donors and stimulated using CD3 and CD28 antibodies in combination with recombinant IL-2 . To investigate the immunological role ofSLC16A7, co-culture experiments were performed between BCa cells and activated CD8 + T cells. Additionally, CD8 + T cell chemotaxis assays and ELISA analyses were conducted to evaluate the immune responses mediated by SLC16A7.  \nResults SLC16A7 expression was downregulated in 16 cancer types, including BCa, and upregulated in three cancer types. Its expression was significantly associated with tumor stage in four cancers and showed both positive and negative correlations with prognosis, depending on the cancer type. Genomic analyses revealed significant associations between SLC16A7 and TMB in 13 cancer types and MSI in 11 cancer types. Pathway enrichment analyses (Hallmark-GSEA and KEGG-GSEA) indicated strong associations between SLC16A7, immune responses, and tumor progression. Immune infiltration analysis showed a predominantly positive association between SLC16A7 expression and immune cell infiltration, except in low-grade gliomas (LGG) . CIBERSORT analysis demonstrated that  \n†Mingjie Xu and Jiatong Zhou contributed equally to this work.  \n*Correspondence: Jiancheng Lv [1324089@zju.edu.cn](1324089@zju.edu.cn)[ ](1324089@zju.edu.cn)Yu Zhang [1028787131@qq.com](1028787131@qq.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use i","cbCaidRl9tQQoi8W","https://ap.wps.com/l/cbCaidRl9tQQoi8W","pdf",8333022,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What role does SLC16A7 play in cancer based on this study?\",\"answer\":\"SLC16A7 shows tumor-suppressive properties, with downregulation in most cancers and links to better prognosis in bladder cancer. It is also associated with immune response signatures and improved survival outcomes.\"},{\"question\":\"How was SLC16A7 analyzed across cancers?\",\"answer\":\"The study used comprehensive pan-cancer data from 33 tumor datasets, assessing relationships between SLC16A7 expression and clinicopathological features, prognosis indicators, TMB, MSI, immune infiltration, and immune-related gene expression.\"},{\"question\":\"What experimental evidence supports the findings in bladder cancer?\",\"answer\":\"BCa tissue and cell line measurements showed reduced SLC16A7 expression versus normal counterparts. Functional assays indicated that SLC16A7 inhibits BCa progression and promotes CD8+ T cell chemotaxis and tumor-killing in the tumor microenvironment.\"}]","Tumor suppressing function of SLC16A7 in bladder cancer and its pan-cancer analysis | PDF",1790161563,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f612ad734a001093883c5c5cdee63b27.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a20f8488d97ee1020d265c674c9c0465.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a97d33f8572d0a5d5ffe92ef458baa0f.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1ea3e83c5b635f42ffc8600a694de104.webp",980,1306]